<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814916</url>
  </required_header>
  <id_info>
    <org_study_id>DUR001-306</org_study_id>
    <secondary_id>2014-005281-30</secondary_id>
    <nct_id>NCT02814916</nct_id>
  </id_info>
  <brief_title>Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute
      bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive),
      known or suspected to be caused by susceptible Gram-positive organisms, including
      methicillin-resistant strains of Staphylococcus aureus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with abnormal audiologic assessment</measure>
    <time_frame>Baseline to Day 28 (± 2 days)]</time_frame>
    <description>Audiologic testing will be conducted in at least 7 children less than 2 years old (at least 3 of which are neonates) and will include evoked otoacoustic emissions testing, acoustic immittance measures (tympanometry and contra and ipsilateral acoustic reflex thresholds) and (optional) threshold auditory brainstem responses. Patients with an abnormal audiologic assessment at Day 28 (plus or minus 2 days) that exceeds, by a clinically significant margin, any abnormality observed in the Baseline assessment, will be considered to have an abnormal audiologic assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora</measure>
    <time_frame>Baseline to Day 28 (± 2 days)</time_frame>
    <description>Evaluated in patients from birth to &lt; 2 years of age, by performing polymerase chain reaction (PCR) for Clostridium difficile (C diff) and culture for vancomycin-resistant enterococci (VRE) on a stool specimen or rectal swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Baseline to 48 - 72 hours</time_frame>
    <description>Defined as greater than 20% reduction in lesion size compared to baseline. In patients diagnosed with ABSSSI age birth to &lt; 3 months, clinical response at 48-72 hours post-randomization is defined as cessation of increase in lesion size and decreased erythema or tenderness compared to baseline with no appearance of new lesions. In patients diagnosed with sepsis age birth to &lt; 3 months, clinical response at 48-72 hours post-randomization is defined as improvement of at least one abnormal clinical and laboratory parameter related to sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Cure</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Improvement</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Improvement will be defined as a reduction in severity of two or more, but not all, clinical signs and symptoms of infection, when compared with baseline (patients age 3 months to 17 years and ABSSSI patients age birth to &lt;3 months). In sepsis patients age birth to &lt; 3 months, improvement is defined as reduction in severity of at least one abnormal clinical and laboratory parameter related to sepsis, when compared with baseline. In patients age 3 months to 17 years, no additional antibacterial treatment is required for disease under study. In patients age birth to &lt; 3 months, no rescue antibiotics required after at least 48 hours of start of study treatment. This outcome category will only be used at the EOT evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Failure</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Unknown</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure, Improvement or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Cure</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Failure</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Unknown</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Cure</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Failure</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Unknown</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of baseline pathogen after treatment</measure>
    <time_frame>Baseline to Day 54 (± 7 days)</time_frame>
    <description>Direct demonstration of eradication or persistence of the causative organism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality: For patients age birth to &lt; 3 months, all-cause mortality will be determined at test of cure (TOC) visit</measure>
    <time_frame>Baseline and Day 28 (± 2 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalbavancin plasma concentration</measure>
    <time_frame>Within 14 (± 2) days of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <condition>Bacterial Infections</condition>
  <condition>Staphylococcal Skin Infections</condition>
  <arm_group>
    <arm_group_label>Dalbavancin, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalbavancin, two doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin single dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.
Patients age birth to &lt;3 months will only receive the single-dose regimen of dalbavancin; any concomitant antibacterial therapy may be administered in this age group based on local standard of care.</description>
    <arm_group_label>Dalbavancin, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin two dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.</description>
    <arm_group_label>Dalbavancin, two doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA).
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.
Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns.
No patient age birth to &lt; 3 months will be randomized to the comparator arm.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In patients age 3 months to 17 years (inclusive):

               1. Male or female patients 3 months to 17 years (inclusive)

               2. A clinical picture compatible with Acute Bacterial Skin and Skin Structure
                  Infections (ABSSSI) suspected or confirmed to be caused by Gram-positive
                  bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).

               3. In addition to local signs of ABSSSI, the patient has at least one of the
                  following:

                    1. Fever, defined as body temperature ≥ 38.4°C (101.2°F) taken orally, ≥ 38.7°C
                       (101.6°F) tympanically, or ≥ 39°C (102.2°F) rectally (core temperature) OR

                    2. Leukocytosis (WBC &gt; 10,000 mm3) or leukopenia (WBC &lt; 2,000 mm3) or left
                       shift of &gt;10% band neutrophils

               4. Infection either involving deeper soft tissue or requiring significant surgical
                  intervention:

                  a. Major cutaneous abscess characterized as a collection of pus within the dermis
                  or deeper that is accompanied by erythema, edema and/or induration which: i.
                  requires surgical incision and drainage, and ii. is associated with cellulitis
                  such that the total affected area involves at least 35 cm2 of erythema, or total
                  affected area of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR iii.
                  alternatively, involves the central face and is associated with an area of
                  erythema of at least 15 cm2 b. Surgical site or traumatic wound infection
                  characterized by purulent drainage with surrounding erythema, edema and/or
                  induration which occurred within 30 days after the trauma or surgery and is
                  associated with cellulitis such that: i. the total affected area involves at
                  least 35 cm2 of erythema, or total affected area of erythema is at least BSA (m2)
                  x 43.0 (cm2/m2), OR ii. alternatively, involves the central face and is
                  associated with an affected area of at least 15 cm2 c. Cellulitis, defined as a
                  diffuse skin infection characterized by spreading areas of erythema, edema and/or
                  induration and: i. is associated with erythema that involves at least 35 cm2 of
                  surface area, or surface area of erythema is at least BSA (m2) x 43.0 (cm2/m2),
                  OR ii. alternatively, cellulitis of the central face that is associated with an
                  affected area of at least 15 cm2

               5. In addition to the requirement for erythema, all patients are required to have at
                  least two (2) of the following signs of ABSSSI:

                    1. Purulent drainage/discharge

                    2. Fluctuance

                    3. Heat/localized warmth

                    4. Tenderness to palpation

                    5. Swelling/induration

          -  In patients age birth to &lt; 3 months, each patient must meet the following inclusion
             criteria to be enrolled in this study.

               1. Male or female patients from birth to &lt; 3 months of age, including pre-term
                  neonates (gestational age ≥ 32 weeks)

               2. A clinical picture compatible with an ABSSSI suspected or confirmed to be caused
                  by Gram-positive bacteria, including MRSA.

                  OR

                  Suspected or confirmed sepsis including any of the following clinical criteria:

                    1. Hypothermia (&lt;36°C) OR fever (&gt;38.5°C)

                    2. Bradycardia OR tachycardia OR rhythm instability

                    3. Hypotension OR mottled skin OR impaired peripheral perfusion

                    4. Petechial rash

                    5. New onset or worsening of apnea episodes OR tachypnea episodes OR increased
                       oxygen requirements OR requirement for ventilation support

                    6. Feeding intolerance OR poor sucking OR abdominal distension

                    7. Irritability

                    8. Lethargy

                    9. Hypotonia

               3. In addition, patients must meet at least one of the following laboratory
                  criteria:

                    1. White blood cell count ≤4.0 × 109/L OR ≥20.0 × 109/L

                    2. Immature to total neutrophil ratio &gt;0.2

                    3. Platelet count ≤100 × 109/L

                    4. C-reactive protein (CRP) &gt;15 mg/L OR procalcitonin ≥ 2 ng/mL

                    5. Hyperglycemia OR Hypoglycemia

                    6. Metabolic acidosis

               4. Infections must be of sufficient severity to merit hospitalization and parenteral
                  antibiotic therapy. These infections may include:

                    1. Cutaneous or subcutaneous abscess

                    2. Surgical site or traumatic wound infection

                    3. Cellulitis, Erysipelas

                    4. Omphalitis

                    5. Impetigo and bullous impetigo

                    6. Pustular folliculitis

                    7. Scarlet fever

                    8. Staphylococcal scalded skin syndrome

                    9. Streptococcal toxic shock syndrome

                   10. Erythematous based-erosion

                   11. Other infections originating in the skin or subcutaneous tissue and
                       associated with signs and symptoms of sepsis as defined in Inclusion
                       Criterion 2.

               5. Patients must be expected to survive with appropriate antibiotic therapy and
                  appropriate supportive care throughout the study.

        Exclusion Criteria:

          1. Patients age 3 months to 17 years: Clinically significant renal impairment, defined as
             calculated creatinine clearance of less than 30 mL/min. (calculated by the Schwartz
             &quot;bedside&quot; formula). Patients birth to &lt; 3 months of age: Moderate or severe renal
             impairment defined as serum creatinine ≥ 2 times the upper limit of normal (× ULN) for
             age OR urine output &lt; 0.5 mL/kg/h (measured over at least 8 hours prior to dosing) OR
             requirement for dialysis.

          2. Clinically significant hepatic impairment, defined as serum bilirubin or alkaline
             phosphatase greater than 2 times the upper limits of normal (ULN) for age, and/or
             serum aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3
             times the upper limits of normal (ULN) for age.

          3. Treatment with an investigational drug within 30 days preceding the first dose of
             study medication.

          4. Patients with sustained shock defined as systolic blood pressure &lt; 90 mm Hg in
             children ≥ 10 years old, &lt; 70 mm Hg + [2 x age in years] in children 1 to &lt;10 years,
             or &lt; 70 mmHg in infants 3 to &lt;12 months old for more than 2 hours despite adequate
             fluid resuscitation, with evidence of hypoperfusion or need for sympathomimetic agents
             to maintain blood pressure.

          5. More than 24 hours of any systemic antibacterial therapy within 96 hours before
             randomization. EXCEPTION: Microbiological or clinical treatment failure with a
             systemic antibiotic other than IV study drug that was administered for at least 48
             hours. Failure must be confirmed by either a microbiological laboratory report or
             documented worsening clinical signs or symptoms.

          6. Infection due to an organism known prior to study entry to be resistant to dalbavancin
             (dalbavancin minimum inhibitory concentration (MIC) greater than 0.25 ug/mL) or
             vancomycin (vancomycin minimum inhibitory concentration (MIC) greater than 2 ug/mL).

          7. Patients with necrotizing fasciitis, or deep-seated infections that would require &gt; 2
             weeks of antibiotics (e.g., endocarditis, osteomyelitis or septic arthritis).

          8. Infections caused exclusively by Gram-negative bacteria (without Gram-positive
             bacteria present) and infections caused by fungi, whether alone or in combination with
             a bacterial pathogen.

          9. Venous catheter entry site infection.

         10. Infections involving diabetic foot ulceration, perirectal abscess or a decubitus
             ulcer.

         11. Patient with an infected device, even if the device is removed. Examples include
             infection of: prosthetic cardiac valve, vascular graft, a pacemaker battery pack,
             joint prosthesis, implantable pacemaker or defibrillator, intraaortic balloon pump,
             left ventricular assist device, or a neurosurgical device such as a ventricular
             peritoneal shunt, intra-cranial pressure monitor, or epidural catheter.

         12. Gram-negative bacteremia, even in the presence of Gram-positive infection or
             Gram-positive bacteremia. Note: If a Gram-negative bacteremia develops during the
             study, or is subsequently found to have been present at Baseline, the patient should
             be removed from study treatment and receive appropriate antibiotic(s) to treat the
             Gram-negative bacteremia.

         13. Patients whose skin infection is the result of having sustained full or partial
             thickness burns.

         14. Patients age 3 months to 17 years, with uncomplicated skin infections such as
             superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple
             abscess that only requires surgical drainage for cure. Patients birth to &lt; 3 months of
             age may be enrolled if they have uncomplicated skin infections of sufficient severity
             to require hospitalization and parenteral antibiotic therapy.

         15. Patients age 3 months to 17 years: Concomitant condition requiring any antibiotic
             therapy that would interfere with the assessment of study drug for the condition under
             study.

         16. Sickle cell anemia

         17. Cystic fibrosis

         18. Anticipated need of antibiotic therapy for longer than 14 days.

         19. Patients who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI.

         20. More than 2 surgical interventions (defined as procedures conducted under sterile
             technique and typically unable to be performed at the bedside) for the skin infection,
             or patients who are expected to require more than 2 such interventions.

         21. Medical conditions in which chronic inflammation may preclude assessment of clinical
             response to therapy even after successful treatment (e.g., chronic stasis dermatitis
             of the lower extremity).

         22. Immunosuppression/immune deficiency, including hematologic malignancy, recent bone
             marrow transplant (in post-transplant hospital stay), absolute neutrophil count &lt; 500
             cells/mm3, receiving immunosuppressant drugs after organ transplantation, receiving
             oral steroids ≥ 20 mg prednisolone per day (or equivalent) for &gt; 14 days prior to
             enrollment, and known or suspected human immunodeficiency virus (HIV) infected
             patients with a CD4 cell count&lt; 200 cells/mm3 or with a past or current acquired
             immunodeficiency syndrome (AIDS)-defining condition and unknown CD4 count.

         23. Known or suspected hypersensitivity to glycopeptide antibiotics, betalactam agents,
             aztreonam, or cephalosporins.

         24. Patients with a rapidly fatal illness, who are not expected to survive for 3 months.

         25. Positive urine (or serum) pregnancy test at screening (post-menarchal females only) or
             after admission (prior to dosing).

         26. Pregnant or nursing females; sexually active females of childbearing potential who are
             unwilling or unable to use adequate contraceptive precautions. Female patients to have
             pregnancy testing are those who are at least 10 years old with menarche and/or
             thelarche (beginning of breast development).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urania Rappo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan, plc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Registries Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maricopa Integrated Health System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-344-1949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southbay Pharma Research</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-827-1899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles campus</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-206-2439</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revival Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Global Research Holdings, LLC</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Health Sciences Center dba Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>813-844-7609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-4134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Childen's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Missouri Dermatology and Skin Surgery</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-263-5680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>315-464-7353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos Dr. Orlando Alassia</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000CII</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grodno Regional Infectious Disease Hospital</name>
      <address>
        <city>Grodno</city>
        <zip>230030</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mogilev Regional Children's Hospital</name>
      <address>
        <city>Mogilev</city>
        <zip>212026</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Center for Children</name>
      <address>
        <city>Vitebsk</city>
        <zip>210015</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center - 1 Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+359 6753 34 68</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment - &quot;Deva Maria&quot; EOOD Burgas (UMHAT Deva Maria) Surgery Department</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT (Multiprofile Hospital for Active Treatment)</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT (University Multiprofile Hospital for Active Treatment) Dr. Georgi Stranski, EAD Pediatric Clinic</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT (University Multiprofile Hospital for Active Treatment) Dr. Georgi Stranski, EAD Second Surgery Clinic</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35964886581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment ( UMHAT) &quot;Sveti Georgi&quot; EAD, Plovdiv Department of pediatric surgery - pediatric surgery</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35932-602-207</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;UMHAT (University Multiprofile Hospital for Active Treatment) Sveti Georgi EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev AD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>359 888 209 200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHATEM (University Multiprofile Hospital for Active Treatment and Emergency Medicine) N.I.Pirogov Septic Surgery Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pediatric Diseases Prof. Ivan Mitev EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35 928154222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment (UMHAT)</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos Dr. Roberto del Rio</name>
      <address>
        <city>Independencia</city>
        <state>RM</state>
        <zip>&quot;8380418</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Vicente de Paul en Medellin</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>50010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Medellin Luz Castro de Gutierrez</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>500515</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardio Infantil</name>
      <address>
        <city>Bogota</city>
        <zip>110131</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de la Sabana</name>
      <address>
        <city>Chia</city>
        <zip>25175</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD M. Iashvili Children's Central Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti Children New Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Athens Attikon 3rd Department of Pediatrics</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aghia Sophia Childrens Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;General Childrens Hospital of Athens P A Kyriakou</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>30 6974420425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital Paidon Pentelis</name>
      <address>
        <city>Athens</city>
        <zip>15236</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital Paidon Pentelis</name>
      <address>
        <city>Athens</city>
        <zip>15236</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>213 2052362</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki Aristotle University, 3rd Dept</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Papageorgiou General Hospital of Thessaloniki, 4th Department of Pediatrics, Aristotle University of Thessaloniki, School of Medicine</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Medica Especializada en Pediatria</name>
      <address>
        <city>Guatemala</city>
        <zip>01004</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Roosevelt Pediatric Department, 3rd floor</name>
      <address>
        <city>Guatemala</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Centro Medico Infectology Department</name>
      <address>
        <city>Guatemala</city>
        <zip>01016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital</name>
      <address>
        <city>Liepaja</city>
        <state>Kurzeme</state>
        <zip>LV-3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda Children's Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT- 92144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Public Institution Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08046</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Dr. Agustin O'Horan</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>52 99 9923 8673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria</name>
      <address>
        <city>Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez</name>
      <address>
        <city>Mexico</city>
        <zip>6720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>(55) 5228 9917</phone>
      <phone_ext>2331</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Materno Infantil José Domingo de Obaldía</name>
      <address>
        <city>Chiriqui</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-775-4221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Del Niño Dr. José Renán Esquivel</name>
      <address>
        <city>Panama City</city>
        <zip>0816-00383</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Obserwacyjno-Zakaźny</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-Pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048 52 3255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <state>Województwo Wielkopolskie</state>
        <zip>61-825</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048 61 8590 338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048 (22) 508-12-20</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Craiova</name>
      <address>
        <city>Craiova</city>
        <state>Jud. Dolj</state>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urganta pentru Copii &quot;Sfanta Maria&quot; Iasi</name>
      <address>
        <city>Iasi</city>
        <state>Jud. Iasi</state>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judeatean Mures</name>
      <address>
        <city>Targu Mures</city>
        <state>Jud. Mures</state>
        <zip>540342</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timisoara</city>
        <state>Jud. Timis</state>
        <zip>500063</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase &quot;Prof. Dr. Matei Bals&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Tropicale &quot;Dr. Victor Babes&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>30303</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>40 722816886</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vologda Regional Children's Clinical Hospital</name>
      <address>
        <city>Vologda</city>
        <state>Vologda Region</state>
        <zip>160022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>920 1256440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical University</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>74 812611301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavropol State Medical University</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peermed Clinical Trial Centre</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2710 020 2428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mzansi Ethical Research Centre</name>
      <address>
        <city>Middelburg</city>
        <zip>1050</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia-San Sebastian</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>91 5 29 00 26</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre Edificio Materno Infantil, Servicio de Pediatria</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>91 390 8569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 609033285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15076</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 981 950 610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>609033285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central City Clinical Hospital, Pediatric Surgery Department, State Institution of higher Education &quot;Uzhhorod National University&quot;, Faculty of Postgraduate Education and Pre-University Preparation, Chair of Surgical Specialties</name>
      <address>
        <city>Uzhhorod</city>
        <state>Zakarpatska Region</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Dnipropetrovsk Regional Children's Clinical Hospital&quot;&quot; Dnipropetrovsk Regional Council&quot;&quot;, Surgery department, State Institution &quot;&quot;Dnipropetrovsk Medical Academy of MoH of Ukraine&quot;&quot;, Chair of Pediatric surgery</name>
      <address>
        <city>Dnipro</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Surgery Department, Ivano-Frankivsk Regional Pediatric Clinical Hospital,</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PE PMC Acinus</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lviv National Medical University</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Higher State Educational Institute of Ukraine &quot;Ukrainian Medical Stomatological Academy&quot; based on Children's City Clinical Hospital of Poltava City</name>
      <address>
        <city>Poltava</city>
        <zip>36004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
    <mesh_term>Staphylococcal Skin Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

